Compare Eli Lilly And Co (LLY) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Annaly Capital Management, Inc. — how do they compare? Eli Lilly And Co trades at $1,222.3 (market cap $1.08T), while Annaly Capital Management, Inc. trades at $23.33 (market cap $17.44B). The key difference: Eli Lilly And Co is far larger — about 61.9× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (12.96%). Which is the better fit depends on your goals.
| LLY | NLY | |
|---|---|---|
Market Cap | $1.08T | $17.44B |
Sector | Health | Financials |
52-Week High | $1.24K | $24.40 |
52-Week Low | $639.43 | $20.21 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
NLY trades at $23.28, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.59 and a high ROE of 20.66%. Recent quarterly earnings have consistently beaten estimates, and the company maintains a significant dividend yield. Analyst consensus is positive, with a $24.50 price target, supported by recent upgrades and institutional buying activity.
The outlook for NLY is favorable, driven by earnings growth and a high dividend yield, but risks include interest rate sensitivity and high leverage. The stock offers value and income appeal, yet investors should weigh the cyclical nature of the mortgage REIT sector against the strong analyst support and recent financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
